Merck Halts Blood Thinner Study
January 13, 2011 at 12:48 PM EST
Merck & Co. Inc. (NYSE: MRK) cited safety concerns for halting one clinical trial of its blood thinner vorapaxar and changing a second study. Shares of the healthcare company tumbled $2.37 to $34.78.
